PHVS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

PHVS ▲ +3.08% at T+5d

NEUTRAL call ✓ call won +3.08% · α vs SPY +5.61% · entry $30.16 → $31.09

Next anchor: T+20d in 14d

Last close $30.72 (close Jun 12) · +1.86% from $30.16 entry

Entry anchored
May 29, 2026
via day open

T+1d

-3.51%

call -3.51% · α -3.77%

$29.10

settled 14d ago

T+5d

+3.08%

call +3.08% · α +5.61%

$31.09

settled 10d ago

T+20d

—

call — · α —

—

in 14d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 congress, including Phase 3 RAPIDe-3 on-demand HAE data and Phase 2 CHAPTER-1 OLE prophylaxis data. The event is a routine scientific conference update with no new clinical data released today; the key catalyst remains the CHAPTER-3 topline data expected in Q3 2026.

Actionable Insight

This is a routine conference update with no new data released. The next major catalyst is CHAPTER-3 topline data in Q3 2026. Monitor EAACI presentations for any incremental safety/efficacy signals, but no immediate trading action warranted.

Key Facts

8 abstracts accepted at EAACI 2026 (June 12-15, Istanbul), including 1 oral presentation of RAPIDe-3 Phase 3 on-demand HAE data
7 additional presentations cover cardiovascular safety, biomarker assay, RAPIDe-3 patient voices, and CHAPTER-1 OLE prophylaxis results
CHAPTER-3 global pivotal Phase 3 study of deucrictibant XR for HAE prophylaxis ongoing; topline data expected Q3 2026
CREAATE Phase 3 study for AAE-C1INH (prophylactic and on-demand) also ongoing
No new clinical data or regulatory milestones announced in this press release

Financial Impact

No financial data disclosed; event is a scientific conference update with no revenue or cost implications

Risk Factors

No new clinical data released today; market may be disappointed by lack of material update
CHAPTER-3 topline data in Q3 2026 is binary risk for the stock
Competitive landscape includes existing injectable HAE therapies (Takhzyro, Firazyr) and oral competitors (Orladeyo)

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (20 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3303489

23 reports for PHVS

T+1T+5T+20T+60

80% Hit rate 4 of 5 directional calls best @ T+20▲ +11.42%Mar 20, 2026

Filters

Reports for PHVS — sortable, filterable
	Type				Now
May 29, 2026 16d ago	Press Release NEUTRAL ★ 4/10	$30.16 $31.09	▲ +3.08%	▲ +5.61%	$30.72 (+1.86%)
May 26, 2026 19d ago	Insider Cluster NEUTRAL ★ 4/10	$29.47 $30.14	▲ +2.27%	▲ +1.80%	$30.72 (+4.24%)
May 26, 2026 19d ago	Insider Cluster BEARISH ★ 5/10	$29.47 $30.14	▼ −2.27%	▼ −1.80%	$30.72 (−4.24%)
May 22, 2026 23d ago	Insider Cluster NEUTRAL ★ 3/10	$29.68 $29.10	▼ −1.95%	▼ −3.63%	$30.72 (+3.50%)
May 21, 2026 24d ago	144 NEUTRAL ★ 3/10	$29.68 $29.10	▼ −1.95%	▼ −3.61%	$30.72 (+3.50%)
May 20, 2026 25d ago	Insider Cluster NEUTRAL ★ 3/10	$30.54 $30.16	▼ −1.24%	▼ −3.09%	$30.72 (+0.59%)
May 20, 2026 25d ago	144 NEUTRAL ★ 2/10	$30.54 $30.16	▼ −1.24%	▼ −3.09%	$30.72 (+0.59%)
May 19, 2026 26d ago	Insider Cluster NEUTRAL ★ 4/10	$29.45 $29.86	▲ +1.39%	▼ −0.41%	$30.72 (+4.31%)
May 12, 2026 4w ago	Press Release NEUTRAL ★ 5/10	$32.94 $28.95	▼ −12.11%	▼ −10.95%	$30.72 (−6.74%)
May 11, 2026 4w ago	6-K NEUTRAL ★ 4/10	$31.25 $28.81	▼ −7.81%	▼ −7.89%	$30.72 (−1.70%)

US Market Status

Market Closed — Opens in 3h 29m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access